HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
18 Citations
62 Claims
-
1-42. -42. (canceled)
-
43. A method of treating a hypogonadal male subject, said method comprising:
-
(a) Orally administering to said male subject a daily dosing regimen of a pharmaceutical composition comprising about 14 weight % (wt %) to about 35 wt % testosterone undecanoate and a carrier, that provides from about 360 mg to about 480 mg of testosterone undecanoate to said male subject per day; (b) Determining the serum level of testosterone of said male subject during the daily dosing regimen at from 1-8 hours after single dose administration of said pharmaceutical composition at steady state; and (c) Orally administering a maintenance daily dosing regimen of a pharmaceutical of a pharmaceutical composition comprising about 14 wt % to about 35 wt % testosterone undecanoate and a carrier, that provides within plus or minus 40% of from about 360 mg to about 480 mg of testosterone undecanoate to said male subject based on the serum testosterone level determined in step (b), to provide a serum testosterone Cave in said male subject in the range of from about 300-1100 ng/dL. - View Dependent Claims (44, 45, 46, 47, 48, 49, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61)
-
-
53. A method of treating a hypogonadal male subject having testosterone deficiency said method comprising:
-
(a) Orally administering to said male subject a daily dosing regimen of a pharmaceutical composition comprising about 14 wt % to about 35 wt % testosterone undecanoate and a carrier to provide from about 350 mg testosterone undecanoate to about 650 mg testosterone undecanoate to said male subject per day; (b) determining the serum level of testosterone of said male subject during the daily dosing regimen at a single time point from 1-8 hours after single dose administration of said pharmaceutical composition at steady state, Ct; and (c) orally administering a maintenance daily dosing regimen of a pharmaceutical of a pharmaceutical composition comprising about 14 wt % to about 35 wt % testosterone undecanoate and a carrier, that provides within plus or minus 40% of from about 350 mg to about 650 mg of testosterone undecanoate to said male subject based on the serum testosterone level determined in step (b), said carrier comprising a monoglyceride, a diglyceride, a fatty acid, a polyoxyethylene hydrogenated vegetable oil or a combination thereof, to provide a serum testosterone Cave in said male subject in the range of from about 300-1100 ng/dL.
-
-
62. A method of treating a hypogonadal male subject said method comprising:
-
(a) Orally administering to said male subject a daily dosing regimen of a pharmaceutical composition comprising about 14% to about 35% testosterone undecanoate and a carrier to provide from about 360 mg testosterone undecanoate to about 480 mg testosterone undecanoate to said male subject per day; (b) determining the serum level of testosterone of said male subject during the daily dosing regimen at a single time point from 1-8 hours after single dose administration of said pharmaceutical composition at steady state, Ct; and (c) orally administering a maintenance daily dosing regimen of a pharmaceutical of a pharmaceutical composition comprising about 14% to about 35% testosterone undecanoate and a carrier, that provides within plus or minus 40% of from about 360 mg to about 480 mg of testosterone undecanoate to said male subject based on the serum testosterone level determined in step (b), said carrier comprising a monoglyceride, a diglyceride, a polyoxyethylene hydrogenated vegetable oil or a combination thereof and said pharmaceutical composition having at least 5% of said testosterone undecanoate not dissolved and at least 33% dissolved, to provide a serum testosterone Cave in said male subject in the range of from about 300-1100 ng/dL.
-
Specification